Additional European Equity News
Babcock (BAB LN) - FY 2026 (GBP): Revenue 5.27bln (exp. 5.12bln), Contract backlog 9.6bln (prev. 10.4bln Y/Y), Underlying Operating Profit 0.29bln (prev. 0.36bln Y/Y), affirms FY27 guidance, supported by good revenue visibility with around 70% revenue under contract. Remain confident in our medium-term guidance of average revenue growth of mid-single digit, underlying operating margin of at least 9% and average underlying operating cash conversion of at least 80%. (Babcock)
InPost (INPST NA) - Q1 2026 (PLN): Revenue 3.86bln (prev. 2.95bln Y/Y), EBIT 209.2mln (prev. 461.7mln Y/Y). InPost delivered 77 million parcels in the UK and Ireland in Q1 2026, a 220% YoY increase driven by strong C2C performance and B2C gains following the consolidation of Yodel. At the Group level for Q2 2026, we anticipate YoY growth in mid- to high- teens percent range. (InPost)
Leg Immobilien (LEG GY) - Q1 2026 (EUR): Adj. EBITDA 183.6mln (prev. 173.4mln Y/Y), AFFO 58.6mln, -5.9% Y/Y. Confirmed its FY26 guidance. (Leg Immobilien)
Novo Nordisk (NOVOB DC) - Novo Nordisk presented new sub-analyses from the Phase 3 OASIS 4 clinical trial, showing the efficacy of Wegovy pill in adults with obesity compared with placebo. Wegovy pill delivered 21.6% weight loss in early responders and doubled mobility improvement. (Novo Nordisk)
Prosiebensat 1 Media (PSM GY) - Q1 2026 (EUR): Adj. EBITDA 44mln (exp. 43mln), Revenue 775mln (prev. 855mln Y/Y). Affirms outlook. (Prosiebensat 1 Media)
Ryanair (RYA ID) - Italy's top court issued a final judgement imposing a total EUR 4.2mln fine to ACGM against the airline, finding that ACGM discriminated by rejecting proposed commitments. (Newswires)
Spirax (SPX LN) - Trading Update: Organic growth in line with expectations across all Businesses; full-year guidance reiterated. In STS, demand grew ahead of IP and in line with our expectations, supported by sustained strength in MRO and solutions across all regions and some recovery in large project demand. Demand in China and Korea also continued to recover. (Spirax)
Verbund (VER AV) - Q1 2026 (EUR): Revenue 2.29bln (prev. 1.93bln Y/Y), EBITDA 723bln (prev. 534bln Y/Y). Expects EBITDA 2.1-2.5bln. (Verbund)
Vistry (VTY LN) - AGM Trading Update: Paused current share buyback programme and further reduced inventory through target sales to enhance cash generation. Expects H1 profit to be significantly lower than the prior year, but H2'26 profit to be in line with H2'25 profit. (Vistry)